EN DE
Watch MedPacto Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MedPacto Inc (235980) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of MedPacto Inc stock KRW 1,234, price KRW 3,550, that is 65.2% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

MI MedPacto Inc logo Thin data Nov 9, 2026

MedPacto Inc

235980 · KQ
Very expensive, weak quality

Our calculation puts a fair price 65% below what the stock costs today.

Low debt
Revenue last quarter +25% vs. a year ago.
Quality 48/100
Fair value 1,234 KRW · Strongly overvalued
Weak Growth
Negative free cash flow
Trails peers (3/8)
Narrow moat 9/100
Thin data
Watch MedPacto Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

63,268 KRW 2,240 KRW Fair Value 1,234 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 2,240 KRW – 63,268 KRW · fair‑value band 814.25 KRW – 1,542 KRW · the 3,550 KRW price screens above the 1,234 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow MedPacto in your weekly email

Every Wednesday you see whether MedPacto is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MedPacto, Inc. engages in the development and sale of marker-based new drugs in South Korea. MedPacto, Inc. was established in 2013 and is based in Seoul, South Korea.

Stock analysis

MedPacto Inc (235980) currently trades at 3,550 KRW, while our model-based Fair Value estimate is 1,234 KRW, 65% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 814.25 KRW (bear) to 1,542 KRW (bull), the price of 3,550 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

MedPacto Inc reported revenue of 3.9B KRW in FY2025 versus 0 KRW in FY2021. Reported net income was −12.8B KRW in FY2025.

Key figures

Market cap 122B KRW (≈ $90.9M) Micro · P/S ratio 20.1 · EPS (TTM) −412.52 KRW · Return on equity −30.8% · Return on assets (EBIT) −33.1% (5-year average) · Operating margin −342% · Revenue (TTM) 5.0B KRW · Revenue growth (YoY) +25.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 56% below its 52-week high and 58% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −65%, 235980 screens richer than that median.

Fair Value models

Bear 814.25 KRW Fair Value 1,234 KRW Bull 1,542 KRW
Price 3,550 KRW · Downside -65.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 814.25 KRW 1,234 KRW 1,542 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 814.25 KRW 1,234 KRW 1,542 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 95
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 71
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

235980 screens overvalued: fair value 65% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare MedPacto Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −65.2% · Below median
Profitability
Return on assets −26.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 25.0% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.65× · Pricier than median
P/S (12 months) 24.36× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)97 · sector 97
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs 235980
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs 235980
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs 235980
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 235980
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs 235980
argenx SE ARGX $962.27 $908.40 −6% vs 235980
CSL Limited CSL A$200.73 A$181.40 −10% vs 235980
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs 235980
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 235980
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs 235980

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MedPacto Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MedPacto Inc Fair Value". https://www.fairvalue-calculator.com/stock/235980

Frequently asked questions

Is MedPacto Inc (235980) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1,234 KRW versus a price of 3,550 KRW, about 65% lower (overvalued).
What is the fair value of 235980?
Our model-based fair value for MedPacto Inc is 1,234 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,550 KRW.
What is the quality score of 235980?
MedPacto Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MedPacto Inc (235980)?
Our model-based price target is the fair value of 1,234 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 814.25 KRW, optimistic scenario 1,542 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MedPacto Inc stock forecast for 2026?
Our models put fair value at 1,234 KRW, about 65% lower versus a price of 3,550 KRW (overvalued). Cautious scenario 814.25 KRW, optimistic scenario 1,542 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MedPacto Inc (235980)?
MedPacto Inc reported trailing-twelve-month revenue of about 5.0B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of MedPacto Inc (235980)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MedPacto Inc it is 1,234 KRW per share (as of Nov 9, 2026), against a price of 3,550 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is MedPacto Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 235980 trades above its calculated fair value: price 3,550 KRW, fair value 1,234 KRW, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 235980?
No. The price is what the market pays today (3,550 KRW); the fair value is what the company's own numbers justify (1,234 KRW). For MedPacto Inc the two are 2,316 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MedPacto Inc worth?
The market values MedPacto Inc at about 122B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,550 KRW; our models calculate a fair value of 1,234 KRW per share.
What do the bullish and bearish scenarios say about 235980?
Our models span a range for MedPacto Inc: cautious scenario 814.25 KRW, base 1,234 KRW, optimistic 1,542 KRW per share (as of Nov 9, 2026, price 3,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MedPacto Inc (235980)?
Balance-sheet figures for MedPacto Inc (as of Nov 9, 2026): return on equity −30.8%, debt of 0.05 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 235980 from its 52-week high?
MedPacto Inc trades at 3,550 KRW, about 56% below its 52-week high of 8,050 KRW and 58% above the low of 2,240 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1,234 KRW is for.
Which stocks are comparable to MedPacto Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MedPacto Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 3,550 KRW, calculated fair value 1,234 KRW (−65%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 235980 calculated?
We run MedPacto Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,234 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. MedPacto Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MedPacto Inc (235980)?
The closing price on Nov 9, 2026 was 3,550 KRW. Our model-based fair value is 1,234 KRW, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MedPacto Inc right now?
The price sits above even our optimistic bull case (1,542 KRW). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (814.25 KRW to 1,542 KRW) leaves room in how you read the outcome.

Key figures of MedPacto Inc

How large is the market capitalisation of MedPacto Inc (235980)?
The market capitalisation of MedPacto Inc is 122B KRW (≈ $90.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MedPacto Inc (235980)?
The price-to-sales ratio of MedPacto Inc is 20.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MedPacto Inc (235980)?
Earnings per share at MedPacto Inc are −412.52 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of MedPacto Inc (235980)?
The return on equity (ROE) of MedPacto Inc is −30.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MedPacto Inc (235980)?
On an EBIT basis the return on assets of MedPacto Inc is −33.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MedPacto Inc (235980)?
The operating margin of MedPacto Inc is −342% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MedPacto Inc (235980)?
Revenue at MedPacto Inc is growing +25.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MedPacto Inc (235980) generate?
The free cash flow of MedPacto Inc is −13.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MedPacto Inc (235980) carry?
The net debt of MedPacto Inc is 59.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MedPacto Inc in the live analysis

One click puts MedPacto Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.